Advice on assistance and protection from the Scientific Advisory Board of the Organisation for the Prohibition of Chemical Weapons : Part 2. On preventing and treating health effects from acute, prolonged, and repeated nerve agent exposure, and the identification of medical countermeasures able to reduce or eliminate the longer term health effects of nerve agents by Timperley, Christopher M. et al.
Accepted Manuscript
Title: Advice on assistance and protection from the Scientific
Advisory Board of the Organisation for the Prohibition of
Chemical Weapons: Part 2. On preventing and treating health
effects from acute, prolonged, and repeated nerve agent
exposure, and the identification of medical countermeasures
able to reduce or eliminate the longer term health effects of
nerve agents
Authors: Christopher M. Timperley, Jonathan E. Forman,
Mohammad Abdollahi, Abdullah Saeed Al-Amri, Augustin
Baulig, Djafer Benachour, Veronica Borrett, Flerida A.
Cariño, Michael Geist, David Gonzalez, William Kane, Zrinka
Kovarik, Roberto Martı́nez-Álvarez, Nicia Maria Fusaro
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Kovarik Z, Martı́nez-Álvarez R, Fusaro Mourão NM, Neffe S, Raza SK, Rubaylo V,
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S, Zaitsev V, Zafar-Uz-Zaman M, Zina MS, Holen S, Alwan WS, Suri V, Advice on
assistance and protection from the Scientific Advisory Board of the Organisation for
the Prohibition of Chemical Weapons: Part 2. On preventing and treating health effects
from acute, prolonged, and repeated nerve agent exposure, and the identification of
medical countermeasures able to reduce or eliminate the longer term health effects of
nerve agents, Toxicology (2018), https://doi.org/10.1016/j.tox.2018.11.009
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Advice on assistance and protection from the Scientific Advisory Board of 
the Organisation for the Prohibition of Chemical Weapons: Part 2. On 
preventing and treating health effects from acute, prolonged, and repeated 
nerve agent exposure, and the identification of medical countermeasures 
able to reduce or eliminate the longer term health effects of nerve agents 
Christopher M. Timperleya,*, Jonathan E. Formanab,**, Mohammad Abdollahib, Abdullah 
Saeed Al-Amric, Augustin Bauligd, Djafer Benachoure, Veronica Borrettf, Flerida A. Cariñog 
Michael Geisth, David Gonzalezi, William Kanej, Zrinka Kovarikk, Roberto Martínez-
Álvarezl, Nicia Maria Fusaro Mourãom, Slawomir Neffen, Syed K. Razao, Valentin Rubaylop, 
Alejandra Graciela Suárezq, Koji Takeuchir, Cheng Tangs, Ferruccio Trifiròt, Francois 
Mauritz van Stratenu, Paula S. Vanninenv, Slavica Vučinićw, Volodymyr Zaitsevx, 
Muhammad Zafar-Uz-Zaman,y Mongia Saïd Zinaz, Stian Holenaa, Wesam S. Alwan,bb Vivek 
Suricc 
a. Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, Wiltshire, 
United Kingdom.  
b. Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran 
University of Medical Sciences, Tehran, The Islamic Republic of Iran. 
c. Saudi Basic Industries Corporation (SABIC), Riyadh, Saudi Arabia. 
d. Secrétariat Général de la Défense et de la Sécurité Nationale (SGDSN), Paris, France. 
e. LMPMP, Faculty of Technology, Ferhat Abbas University, Setif-1, Algeria. 
f. BAI Scientific, Melbourne; and Honorary Fellow, University of Melbourne, Melbourne, 
Australia. 
g. University of the Philippines, Quezon City, Philippines.  
h. BASF SE, Ludwigshafen, Germany. 













j. Consultant to Monsanto Company, Louisiana, United States of America. 
k. Institute for Medical Research and Occupational Health, Zagreb, Croatia.  
l. Complutense University, Madrid, Spain. 
m. Brazilian Chemical Industry, São Paulo, Brazil. 
n. Military University of Technology, Warsaw, Poland. 
o. Institute of Pesticides Formulation Technology (IPFT), Gurugram, Haryana, India. 
p. State Scientific Research Institute of Organic Chemistry and Technology (GosNIIOKhT), 
Moscow, Russian Federation. 
q. Universidad Nacional de Rosario, Consejo Nacional de Investigaciones Científicas y 
Técnicas, Rosario, Argentina. 
r. National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.  
s. Office for the Disposal of Japanese Abandoned Chemical Weapons, Ministry of National 
Defence, Beijing, China. 
t. Department of Industrial Chemistry, University of Bologna, Bologna, Italy.  
u. South African Nuclear Energy Corporation SOC Ltd., Pretoria, South Africa. 
v. VERIFIN, Department of Chemistry, Faculty of Science, University of Helsinki, Helsinki, 
Finland. 
w. National Poison Control Centre, Military Medical Academy, Belgrade, Serbia. 
x. Taras Shevchenko National University of Kyiv, Kyiv, Ukraine; and Pontifical Catholic 
University of Rio de Janeiro, Brazil.  
y. National Engineering and Scientific Commission (NESCOM), Islamabad, Pakistan. 













aa. Secretary to the OPCW Scientific Advisory Board, 2011-2016. 
ab. Secretary to the Scientific Advisory Board and Science Policy Adviser, Organisation for 
the Prohibition of Chemical Weapons (OPCW), The Hague, The Netherlands.  
bb. Intern in the OPCW Office of Strategy and Policy, 2015-2016; Medicinal Chemistry 
Department, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 
3052, Victoria, Australia. 
cc. Intern in the OPCW Office of Strategy and Policy, Summer 2018. 
* Corresponding author. 
** Correspondence to The Organisation for the Prohibition of Chemical Weapons (OPCW), 
The Hague, The Netherlands. 
E-mail addresses: cmtimperley@dstl.gov.uk (C.M. Timperley), jonathan.forman@opcw.org 
(J.E. Forman). 
 





The Scientific Advisory Board (SAB) of the Organisation for the Prohibition of Chemical 
Weapons (OPCW) has provided advice in relation to the Chemical Weapons Convention on 
assistance and protection. We present the SAB’s response to a request from the OPCW 
Director-General in 2014 for information on the best practices for preventing and treating the 
health effects from acute, prolonged, and repeated organophosphorus nerve agent (NA) 
exposure. The report summarises pre- and post-exposure treatments, and developments in 
decontaminants and adsorbing materials, that at the time of the advice, were available for 













unfamiliar with treatment and decontamination options related to exposure to NAs. The SAB 
recommended that developments in research on medical countermeasures and 
decontaminants for NAs should be monitored by the OPCW, and used in assistance and 
protection training courses and workshops organised through its capacity building 
programmes.  
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Upon joining the Chemical Weapons Convention (hereinafter “the Convention”), member 
nations (“States Parties”) commit to never develop, produce, otherwise acquire, stockpile, 
retain or use chemical weapons (OPCW, 1997). The Convention permits the development of 
national programmes for protection against chemical weapons, supported by the Organisation 
for the Prohibition of Chemical Weapons (OPCW), the implementing body of the 
Convention, headquartered in The Hague, the Netherlands. The States Parties to the 
Convention are required to provide assistance and protection to fellow Member States 
threatened by or attacked with chemical weapons, and a State Party may request this 
assistance and protection through the OPCW. Resources from a Voluntary Fund for 
Assistance, as well as individual offers of equipment and trained personnel, are available and 
a network of protection experts consult regularly on means to improve the capabilities of 
States Parties to respond to chemical incidents. Such assistance may include, but is not 
limited to, items such as detection and alarm systems, protective equipment, decontamination 
equipment, medical antidotes and treatments (OPCW, 2016a) and advice on protective 
measures (OPCW, 2017a, 2018a). The OPCW also has a rapid response and assistance 
capability that States Parties can call upon if required (OPCW, 2016b). 
The OPCW has a Scientific Advisory Board (SAB) comprised of 25 members appointed 













scientific and technological fields relevant to the Convention (OPCW, 2018b). This includes 
the provision of advice on technical matters related to international cooperation. At its 
Twentieth Session in June 2013, the Director-General requested the SAB to give advice on 
assistance and protection against chemical weapons (OPCW, 2013). The SAB provided the 
Director-General with a response (OPCW 2014a) that recommended pretreatments and post-
exposure treatments that are available for countering the toxic effects of nerve agent (NA) 
chemical warfare agents (CWAs). This advice forms the substance of Part 1 of this series of 
papers (Timperley et al., 2018a) and that text should be consulted in parallel. 
To capture insight on the long-term damage caused by CWAs, and emerging medical 
countermeasures to them, an additional question was introduced by the Director-General to 
the SAB at its Twenty-First Session in June 2014 (OPCW, 2014b). Then, in light of victims 
of chemical weapons undergoing medical care due to use of the organophosphorus nerve 
agent (NA) sarin in the Syrian Arab Republic (Fischer et al., 2016; Timperley et al., 2018b), 
there was a compelling need to understand better what could be done to mitigate the long 
term effects of CWAs, especially NAs, in humans. Such information would also be a 
valuable addition to the International Support Network for Victims of Chemical Weapons 
that was established by the OPCW in 2011 (OPCW, 2011, 2012). The SAB was thus 
requested to identify any emerging medical countermeasures which could reduce or eliminate 
the long-term health effects arising from acute, prolonged, and repeated exposure to NAs. 
This paper, the second of a series on medical countermeasures and treatment, contains the 
SAB's response provided to the Director-General and States Parties on 10 June 2015 (OPCW, 
2015a). It is augmented by the addition of extra background information and references. 
Adjuncts to traditional medical countermeasure approaches to NA poisoning, including 
neuroprotective agents and bioscavengers, along with methods of decontamination are 
described. The material in this paper assumes familiarity with the previous paper (Part 1: 
Timperley et al., 2018a) which described the medical care and treatment of injuries from 
blister agents and NAs along with experimental and clinical findings. 
Deducing the mechanisms underlying toxic syndromes associated with both classes of CWAs 
is an enduring task (Aas, 2003; Balali-Mood and Abdollahi, 2014; Costanzi et al., 2018; 
Myhrer and Aas, 2014; Myhrer et al., 2006, 2013, 2015; Timperley and Tattersall, 2015). 
This is especially true for organophosphorus (OP) compounds which can cause long-term 













Mood and Balali-Mood, 2008; Brown and Brix, 1998; Karalleide et al., 2006; Hung et al., 
2015; Somani and Husain, 2000; Tattersall, 2018). 
1.1. Legal disclaimer 
This report contains information, guidelines, diagrams and other materials addressed to 
medical practitioners who are engaged in the treatment of casualties of chemical weapons. It 
is made available to the public for information purposes, but is not intended to be used by the 
public. All decisions regarding patient care must be made with a healthcare provider and 
consider the unique characteristics of each patient. The views and opinions expressed in this 
report and in the suggested reading materials are those of the authors and do not reflect the 
views of the OPCW. These materials are cited as a service to readers and do not imply 
endorsement by the OPCW or the individuals involved in the development of this report. The 
OPCW and any of the individuals involved in the development of this report are not 
responsible for the content of third party websites. The information contained herein is 
accurate to the best of the authors’ knowledge. However, neither the OPCW nor the authors 
shall be liable under any circumstances for the correctness, accuracy or comprehensiveness of 
such information, or for the consequences of its use. 
2. Late effects of organophosphorus compounds 
Poisoning from OP compounds produces three principal clinical syndromes: (a) acute 
cholinergic syndrome intermediate syndrome (IMS); and (c) OP-induced neuropathy 
(OPIDN) (Timperley and Tattersall, 2015; Lotti and Moretto, 2005). The acute cholinergic 
crisis develops within minutes to several hours after exposure, depending on the OP 
compound and the route of poisoning (Timperley et al., 2018a). Death can take place in a 
short time if life-threatening conditions, such as respiratory failure, are not treated rapidly and 
appropriately. OPIDN occurs 2-3 weeks following acute exposure to certain OP insecticides 
(Timperley and Tattersall, 2015). The clinical picture is usually a numbness and weakness of 
the lower extremities, followed by progressively ascending weakness of limb muscles. The 
IMS (Senanayake and Karalleide, 1987) occurs in the interval between the end of the acute 
cholinergic crisis and the onset of OPIDN. It is indicated by weakness and fatigue of skeletal 
muscles with fasciculation, leading to paralysis of the respiratory muscles, and is considered 













Neurotoxicity is the main late effect of OP compounds that can occur after an acute exposure 
(Mostafalou and Abdollahi, 2018). The IMS and OPIDN usually occur 24-96 hours and 1 to 
3 weeks after an acute exposure to OP compounds, respectively. The neuropathy can progress 
in months or years after acute and chronic exposure. Persistent inhibition of AChE is initially 
responsible for muscle weakness, but is not the only factor involved in the occurrence of the 
IMS or neuropathy. Therefore, the AChE assay cannot be a sensible index for determining 
nerve and muscle function impairment. IMS usually occurs after an acute cholinergic crisis, 
while a neuropathy may occur after acute and chronic exposures (Karami-Mohajeri et al., 
2014). Studies of acute OP poisoning in experimental animals have revealed that muscle 
necrosis is much more severe in the diaphragm compared to other skeletal muscles 
(Abdollahi and Karami-Mohajeri, 2012). 
Several mechanisms are involved in the etiology of the IMS. They include inhibition of 
acetylcholinesterase (AChE), muscle necrosis, down-regulation or desensitization of 
postsynaptic acetylcholine (ACh) receptors, a failure of presynaptic ACh release, and 
oxidative stress-associated myopathy. In this regard, other factors such as lipophilicity, 
duration of the existence of the main compound or its metabolites in the body, the potency of 
the compound in inhibiting the AChE, severity of influence on repetitive nerve stimulation, 
and type and frequency of the muscle lesions, also matter in the prognosis of the IMS. Plasma 
AChE of less than 200 units and a reduction of 30 Hz repetitive nerve stimulation response 
can help diagnose the IMS (Abdollahi and Karami-Mohajeri, 2012).  
It is well known that respiratory muscle dysfunction is one of the major causes of death in 
acute OP poisoning through muscular paralysis (Seeger et al., 2012). Thus, hypothetically, 
electromyography can help diagnosis but its value is uncertain. Electromyographical changes 
during the IMS include electrical stimulus-induced repetitive and decremental responses, 
tetanic fade, and a decrement-increment response at higher frequencies of repetitive nerve 
stimulation. Normal nerve conduction velocities and distal latency may be noted. The 
recurrent stimulation of nicotinic receptors through presynaptic feedback or desensitization of 
postsynaptic receptors may reduce the release of ACh (Karami-Mohajeri et al., 2014). 
Some of the toxic effect of OP compounds arises from mitochondrial oxidative 
phosphorylation dysfunction mediated through the inactivity of complexes I, II, III, IV and V 
and mitochondrial membrane damage. Reduced synthesis of adenosine triphosphate (ATP) or 













damage mitochondrial antioxidant defences by overproducing reactive oxygen species, 
activating caspases and triggering cell death. This mitochondrial dysfunction is repaired by 
the use of antioxidants such as vitamins E and C, electron donors, and through increasing the 
cytosolic ATP level (Karami-Mohajeri et al., 2013). However, to elucidate many aspects of 
mitochondrial toxicity of OP chemicals, further studies are required. 
Some therapies are underway for the management of chronic neuropathies, especially ones 
related to the oxidative stress that is also evident in OP-induced chronic neuropathy. These 
therapies include taurine, acetyl-L-carnitine, alpha-lipoic acid, protein kinase C inhibitor 
(ruboxistaurin), aldose reductase inhibitors (fidarestat, epalrestat, ranirestat), advanced 
glycation end-product inhibitors (benfotiamine, aspirin, aminoguanidine), the hexosamine 
pathway inhibitor (benfotiamine), and inhibitors of polyADP-ribose, polymerase 
(nicotinamide), and angiotensin-converting enzyme inhibitor (trandolapril) (Hosseini and 
Abdollahi, 2013).  
3. Adjunct agents and new trends in the treatment of nerve agent poisoning 
We now describe a range of drugs that have been tested experimentally for neuroprotective 
purposes in experimental animal models involving prior administration of NAs, sometimes in 
combination with traditional medical countermeasure drugs (e.g. atropine and an oxime). For 
further details of such traditional drug approaches to ameliorating poisoning by OP pesticides 
and NAs (structures of NAs were derived from pesticide research originally; Timperley, 
2000), see Part 1 of this series of papers. The chemical structures of some of the 
neuroprotective drugs now discussed appear in Figure 1. Further details on neuropathology 
and neuroprotective drugs in relation to the treatment of toxicity arising from exposure to 
NAs are available in recently published reviews (Moshiri et al., 2012; Tattersall, 2009; 















Figure 1. Structures of some of the neuroprotective agents tested to alleviate NA poisoning. 
 
3.1. Neuroprotective agents 
3.1.1. Gacyclidine 
Gacyclidine (GK-11) was studied in experimental and clinical trials for different 
neuroprotective indications (Bhagat et al., 2005; Hirbec et al., 2001). It is a new 
phencyclidine derivative that binds to N-methyl-D-aspartate (NMDA) receptors, and also to 
non-NMDA binding sites located in the cerebellum and on the dendritic tree of Purkinje cells. 
Gacyclidine prevents glutamate-induced neuronal death, reduces the size of lesions after 
traumatic brain injury (Smith et al., 2000), and enhances the neuroprotective activity of 
atropine, pralidoxime and diazepam in soman poisoning. The clinical findings and 
electroencephalography (EEG) recordings revealed that convulsions could be prevented in 
soman experiments using primates (Lallement et al., 1999a, 1999b). Optimal effects were 
achieved within 30 min of poisoning. Gacyclidine was useful in inhibiting neuropathological 













Unfortunately, gacyclidine production was stopped several years ago, and the drug is no 
longer available for experimental studies in animals or for clinical trials in humans due to 
patent rights. Ketamine, a weaker NMDA antagonist, with a large clinical use worldwide 
might be considered instead for the treatment of NA-induced refractory status epilepticus 
(Dhote et al., 2012) (see Section 3.1.3. for more information on ketamine as a possible 
neuroprotectant). 
3.1.2. Tezampanel 
Tezampanel (LY293558) is an anti-glutamatergic agent with a specific affinity for kainate 
sub-type receptors (Ornstein et al., 1993). In experimental animals it reduced the length of 
status epilepticus and neuropathy induced by soman (Figueiredo et al., 2011b). The best 
results were achieved when it was administered within 1 h after exposure. Tezampanel can 
prevent brain pathology and is applicable to the paediatric population (Miller et al., 2015). 
3.1.3. Ketamine 
Ketamine is a cyclohexanone derivative that blocks NMDA receptors non-competitively. A 
study with soman-poisoned guinea pigs showed that ketamine effectively stopped the 
seizures and reduced related brain damage when administered 1 h after exposure (Dorandeu 
et al., 2005, 2013). Co-administration of benzodiazepines provided a synergistic effect, and 
when used with atropine, an additional neuroprotective effect (suppression of neutrophil 
granulocyte infiltration and partial suppression of glial activity) (Dhote et al., 2012). The 
additional benefit of ketamine and atropine was explained by NMDA antagonism, possible 
reduction of glutamate release, and the anticholinergic effect of atropine. Similar benefits 
have been observed in mice and rats. However, ketamine is not an approved drug for the 
treatment of NA victims. 
3.1.4. Huperzine A  
Huperzine A is an alkaloid purified from Chinese club moss that is used to treat Alzheimer's 
disease and myasthenia gravis (Zangara, 2003; Zhi et al., 1995). It inhibits AChE reversibly, 
similar to donepezil, rivastigmine or galantamine (Aracava, 2009). A beneficial effect of 













blocking the NMDA receptors (Coleman et al., 2008; Zhang et al., 2001), has been shown in 
animal experiments (Aracava et al., 2009; Garcia et al., 2009; Grunwald et al., 1994). 
3.1.5. Caramiphen 
Caramiphen is an antimuscarinic drug with antiglutamergic and gabaergic properties. Its 
therapeutic efficacy against OP-poisoning as a prophylactic and post-exposure treatment has 
been confirmed in several experimental studies (Figueiredo, 2011a; Raveh et al., 2002, 2014). 
3.1.6. Galantamine 
Galantamine (GAL) inhibits AChE and potentiates ACh-induced currents in brain neurons 
(Aracava, 2009). It also potentiates the activity of NMDA receptors, an action which is 
partially responsible for the improvement of neurocognitive function in patients with 
Alzheimer's disease. In contrast to pyridostigmine and physostigmine that also inhibit 
BuChE, it should help preserve the scavenging capacity of plasma BuChE for OP 
compounds. It crosses the blood-brain barrier, protecting the brain AChE from OP-induced 
irreversible inhibition. Magnetic resonance imaging revealed that galantamine, administered 
30 min prior to exposure of guinea pigs to a lethal dose of soman, prevented brain damage 
(Gullapalli et al., 2010). Galantamine is absorbed rapidly with absolute oral bioavailability 
between 80% and 100%. It has a half-life of 7 h. Peak inhibition of AChE was achieved ~1 h 
after a single oral dose of 8 mg in some healthy volunteers. In one study, performed in guinea 
pigs challenged with 16.8 μg/kg VX (2 × LD50), GAL hydrobromide antagonised VX-
induced lethality, impairment of muscle tension, and EEG changes (Hilmas et al., 2009). 
Optimal clinical effect was found with 10 mg/kg GAL. It did not alter seizure onset induced 
by VX, but significantly decreased seizure duration when administered as a post-exposure 
treatment against 2 × LD50 VX. 
3.1.7. Penehyclidine hydrochloride 
The anticholinergic agent penehyclidine hydrochloride (Niu et al., 1990) has been used 
clinically for treating poisoning by organophosphorus pesticides. Previous studies confirmed 
its ability to cross the blood-brain barrier and antagonise muscarinic and nicotinic receptors 













and had a better neuroprotective effect if administered soon after seizure onset in soman 
poisoning in experimental animals (Wang et al. 2005). 
3.2. Treatments involving inorganic salts 
Treatments involving administration of sodium hydrogen carbonate or magnesium sulfate 
have been investigated for amelioration of OP-poisoning and are discussed next.  
3.2.1. Sodium hydrogen carbonate and blood alkalinisation 
Sodium hydrogen carbonate has been explored as a means of increasing blood alkalinity to 
accelerate the hydrolysis of OP molecules in vivo (Antonijvic et al., 2002; Nurulain, 2012). 
The effects of high doses of sodium hydrogen carbonate (5 milliequivalent/kg (mEq/kg) in 1 
h, followed by 5 mEq/kg/day) were assessed (Vučinić et al., 2009). Adjustment of the dose 
according to the arterial blood gas analysis was necessary. Increasing one unit of pH was 
accompanied by a 10-fold increase in OP hydrolysis, and alkalinisation products of NAs such 
as those from soman were less toxic. Hence, blood alkalinisation may be beneficial in NA 
poisoning. The proposed mechanism involves better control of cardiotoxicity, increased bio-
availability of oximes (Buckley et al., 2011), increased atropine activity, and/or a direct effect 
of sodium hydrogen carbonate on neuromuscular function. The administration of sodium 
hydrogen carbonate is not yet established as a standard procedure. 
 
3.2.2. Magnesium sulfate 
The mechanism of action of magnesium sulfate is inhibition of ACh release through blocking 
calcium channels in the central nervous system (CNS) and at peripheral sympathetic and 
parasympathetic synapses (Fuchs-Buder, 1996). Its efficacy in the treatment of acute OP 
poisoning has been evaluated in several studies: these have shown decreased mortality and 
reduced overstimulation of the CNS due to NMDA receptor activation (Basher and Rahman, 
2013; Eddleston et al., 2008). Doses of 4-16 g of magnesium sulfate were assessed and no 
side effects were observed (Pajoumand, 2004). However, there is still insufficient evidence to 
recommend the routine use of magnesium sulfate for treating NA casualties. 













Besides the inhibition of AChE, the mechanism of OP compound poisoning possibly includes 
induction of oxidative stress and generation of free oxygen radicals (Balali-Mood et al., 2006, 
2012; Moshiri et al., 2012), indicated by the increased activity of catalase, superoxide 
dismutase, glutathione peroxidase, and the concentration of malondialdehyde in red blood 
cells and the liver as a biomarker of oxidative stress (Hosseini and Abdollahi, 2013). Chronic 
toxicity studies have revealed an increased level of oxidative stress biomarkers as well as 
increased DNA damage. A beneficial effect of vitamin E and N-acetyl-L-cysteine has been 
demonstrated in experimental studies. However, there is still insufficient evidence to 
recommend the routine use of drugs that ameliorate oxidative stress in NA casualties. 
3.4. Treatments involving protective bioscavengers 
New treatments to counter NA poisoning should provide reduced lethality, reverse the 
toxicity following exposure, and help eliminate the necessity for further medical intervention. 
The need to start treatment within 1 min after exposure to be effective against poisoning by 
all OP compounds has prompted the development of pretreatment therapy, such as 
bioscavengers (Mann et al., 2018; Moshiri et al., 2012; Mumford et al., 2011, 2013; Rice et 
al., 2016, Masson and Nachon, 2017). Bioscavengers are enzymes, antibodies, or other 
chemicals that sequester and neutralise toxic OP compounds before they reach their 
biological targets (Figure 2). 
If enzymes are to be used as therapeutic agents, they should: 
(a) have a large spectrum of activity versus different NAs and a rapid activity; 
(b) have a suitable retention time in circulation (ideally 11-15 days); 
(c) be available in sufficient concentration to be effective; 
(d) have no immunogenic properties; and 
(e) be available at a reasonable cost. 













(a) Stoichiometric bioscavengers - cholinesterases (ChEs), especially butyrylcholinesterase 
(BuChE) (Boyko et al., 2019; Nicolet et al., 2003), and carboxylesterases (CaEs) (Jokanović 
et al., 1996; Fleming et al., 2007) which react stoichiometrically with OP compounds. 
(b) “Pseudocatalytic bioscavengers” that combine BuChE or AChE, that have scavenging 
properties and bind NAs, and an efficient oxime reactivator, establish cycles of enzyme 
inhibition and reactivation, enabling the degradation of the NAs (Kovarik et al., 2015; Maček 
Hrvat et al., 2016; Radić et al., 2013).  
(c) Catalytic bioscavengers (OP hydrolase, OP anhydrase, and paraoxonase (PON) enzymes 
(Ben-David et al., 2012)) that trap and degrade neurotoxic OP compounds rendering them 
non-toxic (Blum et al., 2008; Briseño-Roa et al., 2006, 2011a, 2011b; Masson et al., 2016; 
Timperley et al., 2006; Worek et al., 2016). Also, cyclodextrins modified with oxime 
functionality are able to encapsulate certain NAs in aqueous media and catalyse their 
hydrolysis to low toxicity products (Zengerle et al., 2011) including the NA acids (Barucki et 
al., 2003; Timperley et al., 2001). 
3.4.1. Stoichiometric bioscavengers 
When used as a pretreatment in mice, fetal bovine serum AChE provided complete protection 
against VX, lower protection against soman, and in conjunction with atropine and 2-PAM in 
a post-exposure treatment, protection against VX and soman (Wolfe et al., 1987). In one 
study on rhesus monkeys, equine serum BuChE protected against 2 × LD50 of soman, and 4 × 
LD50 when atropine was used in the post-exposure treatment (Maxwell et al., 1992). 
Plasma-derived human BuChE (pHuBuChE) scavenging properties against different NAs 
were evaluated in mice, rats (Brandeis, 1993), and rhesus monkeys, and showed a linear 
correlation between the concentration of pHuBuChE and the level of protection against 
soman, sarin and VX. Prophylactic pHuBuChE has several advantages for human use such 
as: rapid reaction with a broad spectrum of OP compounds, a good retention time in 
circulation (Chilukuri et al., 2005), and no immunogenic activity. After extrapolation of data 
from animal experiments to humans, a dose of 200 mg of pHuBuChE has been estimated as a 
prophylaxis for humans in the case of exposure to 2 to 5 × LD50 of soman. For mass 
production of pHuBuChE two methods are currently available: purification of the enzyme 













use of recombinant human enzyme produced in the milk of transgenic goats ('Protexia', 
developed by Nexia) (Cerasoli et al., 2005). Recently an investigation focused on identifying 
a safer source of HuBuChE. Possible sources of recombinant HuBuChE (rHuBuChE) are 
transgenic plants, transgenic animals, transfected larvae, adenovirus or algae, and rHuBuChE 
can also be derived in cell lines. 
CaE is synthesised in the liver and afterwards is present in the circulation in different 
concentrations in mammals. However, humans do not express CaE in their circulation and 
further studies are needed before considering CaE for use as a bioscavenger (Duysen et al., 
2011). 
Fresh frozen plasma (FFP) is a blood fraction prepared by removing the cellular components 
by apheresis. It contains clotting factors, proteins, and enzymes, and is used when these 
components are deficient or lost. It is hypothesised that in OP insecticide poisoning BuChE 
from FFP will sequester the poison present in the blood and remove it from circulation 
(Vučinić et al., 2013). However, the results of limited studies are controversial and there is no 
general agreement that it can be recommended for routine use for the treatment of exposure 















Figure 2. Classes of bioscavengers: (a) stoichiometric bioscavengers react with with NAs to 
form phosphylated adducts with loss of fluoride (G agents) or the N,N-
dialkylethylaminothiolate (V agents) leaving group; (b) pseudocatalytic bioscavengers form 
similar adducts with NAs, but the addition of oximes allows the enzyme to regenerate and the 













release them as non-toxic products and regenerate the original enzyme, which can continue to 
function as a bioscavenger. The protein structures depicted were from the Protein Data Bank, 
and their indentifiers, in parentheses, are: butyrylcholinesterase (1P0I) (Nicolet et al., 2003), 
carboxylesterase (2HRQ) (Fleming et al., 2007), paraoxonase-1 (3SRE) (Ben-David et al., 
2012), and phosphotriesterase (1PSC) (Benning et al., 1995).  
 
3.4.2. Polysialylation of recombinant human BuChE (rHuBuChE) for long-acting NA 
bioscavengers 
Chemical polysialylation of rHuBuChE has been used to produce bioscavengers that are 
stable in the bloodstream (Ilyushin et al., 2013). The CHO-based expression system for 
rHuBuChE resulted in a significant increase in the amount of functional bioscavenger that 
was stable in the blood, with better pharmacokinetic properties, and protection against 4.2 × 
LD50 of O-isobutyl S-2-(diethylamino)ethyl methylphosphonothiolate (VR). 
4. Methods for decontamination of nerve agents 
Decontamination of CWAs is generally based on three methods: (i) mechanical, (ii) physical, 
and (iii) chemical (Mondloch et al., 2015; Rosseinsky et al., 2015; Singh et al., 2010). It was 
described in a separate report by a member of the SAB (Martínez-Álvarez, 2014) and is 
covered in several reviews that should also be consulted (Jang et al., 2015; Yang et al., 1992). 
A decontaminant should be appropriate for the nature of the surface being decontaminated, 
for example bare skin, covered skin, or an inanimate object.  
4.1. Oxidiser gels 
To detoxify a NA, a formulation with a gelling agent (e.g. silica, alumina or aluminosilicate 
clays) and oxidising agent (aqueous sodium hypochlorite) can be prepared at the site of 
decontamination, and applied to the contaminated area (Farahipour et al., 2011). This 














4.2. Bacterial phosphotriesterase 
Phosphotriesterase (PTE) is an enzyme isolated from the bacterium Pseudomonas diminuta 
(Benning et al., 1995). Modified by biotechnological processes, with the redesign of the 
active site, engineered PTE enzymes are useful for detoxifying NAs in vivo (Blum et al., 
2008; Briseño-Roa et al., 2006, 2011a, 2011b; Timperley et al., 2006; Worek et al., 2016). 
4.3. Nanostructured solids and heterogeneous catalysts 
Administration of reactive sorbent materials as oxidation promoters or photocatalysts that are 
activated by sunlight may be considered a new strategy for individual protection and 
decontamination in cases of exposure to CWAs (Wagner, 2010). Oxides of Zn, Ti, Fe, Mn, 
Mg, Al, Zr or Cu have a very high surface area and defective crystalline edges - corners and 
sites that are more reactive than the bulk material. These can be used to decompose NAs into 
non-toxic by-products. Nanomaterials, in particular ZnO-TiO2 nanofibres obtained by 
electrospinning, are suitable for incorporation into textiles and clothes. Catalytically-active 
sites on the surface of zinc titanate fibres enable the slow hydrolysis of some NAs. 
4.4. Nanosized metal oxides as CWA decontaminants 
Having a high surface area, potent adsorbent properties and reactivity towards many CWAs, 
nanosized particles of MgO, Al2O3 and CaO are considered to be promising sorbent materials 
for removing NAs from contaminated surfaces and degrading them, leading to the formation 
of non-toxic products (Wagner et al., 2010). More recently, nanostructured clays and oxides 
for catalytic decontamination of CWAs have been reported (OPCW, 2017b). 
4.5. Nanomaterials as active components in barrier creams 
Identification of nanomaterials that can be used as reactive components of an active 
destructive material to treat a chemically-contaminated area is important (Braue et al., 2005). 
Topical skin protectants have been investigated since 1917, when different soaps and 
ointments were first used; after significant research since 2000, one has been approved by the 
US Food and Drug Administration (FDA), namely Skin Exposure Reduction Paste Against 
Chemical Warfare Agents (SERPACWA) (Braue, 2005, 2011a-b; FDA, 2018; Timperley et 
al., 2018a). Excellent barrier properties are provided by this for protecting against soman and 













fluorinated polyether. Improvement of SERPACWA, by adjusting the amount of active 
nanomaterials, perfluorinated polyether oil, PTFE resin and other additives, increases the 
resistance against sulfur mustard (FDA, 2018).  
5. Summary of response to the Director General’s request 
The responses to the Director-General’s questions by the SAB are now provided: 
(a) Identify best practices for preventing and treating the health effects that arise from acute, 
prolonged and repeated organophosphorus NA exposure 
In the case of prolonged NA exposure, it is necessary to administer the adequate antidotal 
treatment consisting of a reactivator of NA-inhibited AChE, an anticholinergic drug to 
counteract the overstimulation of peripheral and central cholinergic muscarinic receptors, and 
an anticonvulsive drug to prevent centrally-mediated seizures and subsequent tonic-clonic 
convulsions, until the exposure to NA ceases. This treatment must continue as long as NA-
induced clinical and laboratory signs and symptoms are visible. The oxime drugs should be 
administered at a dose regimen that allows the clinical improvement and the normalisation of 
AChE activity or until no further improvement is achieved (Timperley et al., 2018a). 
To regulate repeated administration of reactivators of NA-inhibited AChE, it is important to 
measure the activity of cholinesterases in the blood (erythrocyte AChE and plasma BuChE) 
including a test of reactivation to evaluate the reactivating efficacy of the chosen oxime. 
Anticholinergic drugs should be administered until the signs and symptoms of atropinisation 
appear. Atropinisation should be visible for a longer time (within days). The anticonvulsive 
drugs should be given until the signs and symptoms of disturbed neuromuscular transmission 
and centrally-mediated seizures are visible. To regulate the repeated administration of 
anticonvulsive drugs, it is important to monitor the function of the central and peripheral 
nervous system, including EEG examination and muscle electromyography. Antidotal 
treatment should be supported by symptomatic treatment, including oxygenation, assisted 
ventilation, and the prevention of acidosis and infection, according to the severity of 
poisoning. 
In the case of repeated NA exposure, each exposure must be treated the same way as the first 













that humans can be more sensitive to the acute toxicity of NAs in the case of repeated 
exposure because of the lower activity of AChE in the peripheral nervous system and CNS 
due to previous NA exposures (although changes of the activity of blood ChEs should not be 
very pronounced, monitoring of their activity is necessary). The prognosis of repeated 
exposure to NA is more severe and the antidotal and supportive treatment must be as 
intensive as possible. 
(b) Identify any emerging medical countermeasures, intended for use at the point of exposure 
that can reduce or eliminate longer term health effects arising from acute, prolonged and 
repeated organophosphorus NA exposure. 
The crucial approach - how to reduce or eliminate longer term health effects arising from 
acute, prolonged and repeated NA exposure - is to treat correctly the acute phase of poisoning 
(acute cholinergic crisis). Only rapidly administered adequate antidotal treatment consisting 
of a reactivator of NA-inhibited AChE (preferably the oxime HI-6 or obidoxime), an 
anticholinergic drug (preferably atropine), and an anticonvulsive drug (preferably a 
benzodiazepine), can stop the overstimulation of peripheral and central cholinergic receptors 
and subsequent clinical signs and symptoms. 
Delayed and prolonged effects of NAs are mostly caused by damage to the CNS (frontal 
cortex, piriform cortex, hippocampus, and amygdala) through centrally-mediated seizures 
(due to prolonged overstimulation of central cholinergic muscarinic receptors and subsequent 
activation of glutamatergic receptors). To stop these seizures, it is necessary to prevent 
prolonged stimulation of muscarinic receptors by a centrally-acting anticholinergic drug 
(preferably scopolamine or benactyzine) and an anticonvulsive drug (preferably selected from 
diazepam, alprazolam, or midazolam during the initial seizures; with addition of other drugs 
such as ketamine during refractory status epilepticus that can only be properly treated in 
hospital). The antidotes must be administered as soon as possible to prevent delayed and 
prolonged health effects of NAs. If adequate medical countermeasures are insufficiently 
effective or are not realised sufficiently rapidly after the onset of NA poisoning, longer term 
health effects (especially neurological and including symptoms such as increased excitability 
and a deficit of cognitive function) emerge. In that case, the treatment is insufficient to 
eliminate such damage. However symptomatic and supportive treatment should be 













The development of modern drugs for neuropathies is a need that must be taken into account 
by those researching treatments for OP-poisoning. Due to the potential dangers of 
intermediate syndrome following such poisoning, physicians should be aware of the 
occurrence of delayed neurotoxic effects, and should perform neuromuscular studies to rule 
out other causes and predict the severity of OP intoxication. 
(c) The role of prophylactic antidotes against NAs in the prevention of longer term health 
effects arising from acute, prolonged and repeated exposure to organophosphorus NA 
compounds. 
Prophylactic antidotes against NAs have been developed and introduced into military service 
to increase the resistance of the body against the acute toxicity of NAs and also to increase 
the efficacy of post-exposure antidotal treatment of NA poisoning. Prophylactic antidotes to 
NAs should be administered in response to the threat of exposure to NAs. Generally, the 
combination of the administration of prophylactic antidotes (pretreatment) and post-exposure 
adequate antidote treatment increases the probability of avoiding the delayed and prolonged 
effects of NAs resulting from CNS damage caused by centrally-mediated seizures (via 
protracted overstimulation of central cholinergic muscarinic receptors and the subsequent 
activation of glutamatergic receptors in the CNS). 
Pyridostigmine bromide is a commonly advocated prophylactic antidote against NA 
poisoning (Timperley et al., 2018a). Unfortunately, it has several drawbacks. Its dosage is 
limited due to the risk of adverse effects and it cannot penetrate the blood-brain barrier. Thus, 
pyridostigmine can only protect peripheral AChE against irreversible inhibition by NAs. 
Therefore, a combined oral prophylaxis called PANPAL was developed, in the Czech 
Republic (Bajgar, 2009; Kassa, 2006). Clinical approval from the FDA and European 
Medicines Agency (EMA) would be necessary prior a general recommendation. PANPAL 
consists of a reversible AChE inhibitor (pyridostigmine) to protect peripheral AChE from 
irreversible inhibition by NAs and two centrally-acting anticholinergic drugs (benactyzine 
and trihexyphenidyl; chemical structures provided in Timperley et al., 2018a) to increase 
slightly the dose of pyridostigmine bromide and to antagonise the overstimulation of central 
cholinergic muscarinic receptors. This combination introduced into the Czech Army shows 
higher efficacy than pyridostigmine alone to avoid or at least diminish the acute toxicity and 
to prevent delayed and long-lasting health effects from acute, prolonged and repeated 













Another approach to increase the resistance of humans to NAs and the efficacy of post-
exposure antidotal treatment of poisoning is to administer reactivators of NA-inhibited AChE 
in advance (Timperley et al., 2018a). In the Czech Republic, a special prophylactic antidote 
called TRANSANT (involving the oxime HI-6) was developed and introduced into service in 
the Czech Army (Bajgar, 2009). Clinical approval by the FDA and EMA would be necessary 
prior a general recommendation. This makes it possible to administer percutaneously the 
oxime HI-6 before exposure to NAs. The presence of HI-6 in the bloodstream enables the 
immediate reactivation of NA-inhibited AChE. The combination of both prophylactic 
antidotal means (PANPAL and TRANSANT) represents an effective prevention that is able 
to increase markedly the resistance of humans and prevent the centrally-mediated seizures, as 
well as subsequent delayed and prolonged health effects from acute, prolonged and repeated 
exposure to NAs. 
A recent alternative approach to the development of prophylaxis in the case of threat of 
exposure to NAs is the administration of stoichiometric modified BuChE or catalytic 
bioscavengers (modified paraoxonase or phosphotriesterase) able to bind or hydrolyse NAs 
before they reach the target of their acute toxicity (AChE in the peripheral and central 
nervous system). This type of prophylaxis is valuable, but until now has not been prepared 
for clinical use. However, it represents a promising approach to preventing the longer-term 
health effects arising from acute, prolonged and repeated NA exposure. 
6. Concluding remarks 
This paper concludes the advice on assistance and protection given by the SAB on 
organophosphorus nerve agents to the Director-General and States Parties of the Convention 
in June 2015 (OPCW, 2015a). The findings of the SAB were presented to the delegations of 
States Parties on 8 July 2015 by Dr Slavica Vučinić (OPCW, 2015b) in a lecture held under 
the OPCWs Science for Diplomats initiative. The advice served as the foundation for the 
organisation of an international workshop on “Chemical Warfare Agents: Toxicity, 
Emergency Response and Medical Countermeasures” held in Paris, France, from 26 to 27 
September 2016, that was realised by the OPCW in cooperation with the French Secrétariat 
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 Work of the Organisation of the Prohibition of Chemical Weapons (OPCW) is outlined 
 Advice on assistance and protection from OPCW Scientific Advisory Board is provided 
 Advice addresses medical care and treatment of longer term injuries from nerve agents 
 Scientific literature on the topics is reviewed and over 130 references included 
 This advice will better inform toxicologists, medics and emergency responders 
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